Lobe Sciences Ltd.
LOBEF
$0.027
-$0.0005-1.82%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -84.18% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -84.18% | -- | -- | -- |
| Cost of Revenue | -41.97% | -30.56% | -- | -- | -- |
| Gross Profit | -101.57% | -85.75% | -- | -- | -- |
| SG&A Expenses | -29.22% | -38.92% | -25.88% | -21.07% | -25.85% |
| Depreciation & Amortization | -20.42% | 91.41% | 267.73% | 693.48% | 495.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.73% | -46.71% | 9.62% | -9.43% | -2.11% |
| Operating Income | 26.55% | 37.26% | 18.72% | 34.33% | 26.34% |
| Income Before Tax | -49.13% | 3.96% | 54.31% | 66.09% | 69.80% |
| Income Tax Expenses | -84.33% | -84.33% | -- | -- | -- |
| Earnings from Continuing Operations | -40.65% | 7.49% | 50.89% | 63.44% | 67.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.65% | 7.49% | 50.89% | 63.44% | 67.76% |
| EBIT | 26.55% | 37.26% | 18.72% | 34.33% | 26.34% |
| EBITDA | 27.41% | 38.96% | 21.37% | 19.77% | -37.14% |
| EPS Basic | 1.70% | 36.55% | 77.28% | 84.34% | 86.92% |
| Normalized Basic EPS | 36.62% | 41.38% | 74.30% | 83.43% | 86.45% |
| EPS Diluted | 1.70% | 36.55% | 77.28% | 84.34% | 86.92% |
| Normalized Diluted EPS | 36.62% | 41.38% | 74.30% | 83.43% | 86.45% |
| Average Basic Shares Outstanding | 35.87% | 16.13% | 58.43% | 92.47% | 132.32% |
| Average Diluted Shares Outstanding | 35.87% | 16.13% | 58.43% | 92.47% | 132.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |